ClinicalTrials.gg
CompletedNCT01147055Updated Oct 24, 2011Results posted

Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy Volunteers

A Phase 1 interventional study of crizotinib and rifampin in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-24.

Sponsored by Pfizer · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to estimate the effect of multiple doses of Rifampin on the single dose pharmacokinetics of Crizotinib in healthy volunteers.

02

Conditions studied

  • Healthy

Keywords

  • crizotinib
  • healthy volunteers
  • rifampin
  • pharmacokinetics
  • single dose
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female of non-child bearing potential subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead and clinical laboratory tests).
  • (BMI) of 17.5 to 30.5 kg/m\^2; and a total body weight >50 kg (110 lbs).

Exclusion criteria

Exclusion Criteria:

  • Subjects with evidence of disease, conditions affecting drug absorption, treatment with other drug within 30 days, history of regular alcohol consumption, and use of prescription , nonprescription drugs and dietary supplement within 7 days, and blood donation of 500 mL within 56 days.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    1

    There should be at least 14-day washout period between treatment A and B.

    Drug: crizotinib · Drug: rifampin

Interventions

  • Treatment A: a single 250-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.

  • Treatment B: 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 1 to Day 14.

  • Treatment B: A single 250-mg dose of crizotinib will be administered in the fasted state on Day 9 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

    AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hours (hrs) post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2

  2. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2

Secondary outcomes

  1. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2

  3. Plasma Decay Half-Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2

  4. Apparent Oral Clearance (CL/F)

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose CL/F is influenced by the fraction of the dose absorbed.

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2

  5. Apparent Volume of Distribution (Vz/F)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2

  6. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Crizotinib Metabolite (PF-06260182)

    Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast) of crizotinib metabolite (PF-06260182).

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2

  7. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] for Crizotinib Metabolite (PF-06260182)

    AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞) of crizotinib metabolite (PF-06260182). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2

  8. Time to Reach Maximum Observed Plasma Concentration (Tmax) for Crizotinib Metabolite (PF-06260182)

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2

  9. Maximum Observed Plasma Concentration (Cmax) for Crizotinib Metabolite (PF-06260182)

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2

  10. Metabolite to Parent Ratio Area Under the Curve From Time Zero to Last Quantifiable Concentration (MRAUClast)

    Molar ratio of metabolite to parent area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (MRAUClast).

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2

  11. Metabolite to Parent Ratio Area Under the Curve From Time Zero to Extrapolated Infinite Time [MRAUC (0 - ∞)]

    Molar ratio of metabolite to parent area under the curve from time zero to extrapolated infinite time \[MRAUC (0-∞)\].

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose) , 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2

  12. Metabolite to Parent Ratio Maximum Observed Plasma Concentration (MRCmax)

    Metabolite to parent molar ratio of maximum observed plasma concentration (MRCmax).

    Time frame: 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2

07

Results

Posted Oct 19, 2011

Participant flow

First Intervention Period
Participant flow — First Intervention Period
MilestoneCrizotinib 250 mgCrizotinib 250 mg + Rifampin 600 mg
Started150
Completed140
Not completed10
Withdrew: Lost to follow-up10
Washout Period (at Least 14 Days)
Participant flow — Washout Period (at Least 14 Days)
MilestoneCrizotinib 250 mgCrizotinib 250 mg + Rifampin 600 mg
Started140
Completed140
Not completed00
Second Intervention Period
Participant flow — Second Intervention Period
MilestoneCrizotinib 250 mgCrizotinib 250 mg + Rifampin 600 mg
Started014
Completed014
Not completed00

Outcome measures

PrimaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hours (hrs) post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
ng*hr/mLCrizotinib 250 mgCrizotinib 250 mg + Rifampin 600 mg
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]2192.00 ± 616.59397.20 ± 106.12
Statistical analysis
  • Crizotinib 250 mg vs Crizotinib 250 mg + Rifampin 600 mg · Ratio of adjusted means: 18.21 · 90% CI 16.14 to 20.54
PrimaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLCrizotinib 250 mgCrizotinib 250 mg + Rifampin 600 mg
Maximum Observed Plasma Concentration (Cmax)102.10 ± 35.6432.06 ± 11.23
Statistical analysis
  • Crizotinib 250 mg vs Crizotinib 250 mg + Rifampin 600 mg · Ratio of adjusted means: 31.49 · 90% CI 26.43 to 37.51
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).

Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
ng*hr/mLCrizotinib 250 mgCrizotinib 250 mg + Rifampin 600 mg
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)2103.00 ± 620.52368.60 ± 101.93
Statistical analysis
  • Crizotinib 250 mg vs Crizotinib 250 mg + Rifampin 600 mg · Ratio of adjusted means: 17.60 · 90% CI 15.48 to 20.02
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hrCrizotinib 250 mgCrizotinib 250 mg + Rifampin 600 mg
Time to Reach Maximum Observed Plasma Concentration (Tmax)5.0 (4.0 to 6.0)3.0 (2.0 to 5.0)
SecondaryPlasma Decay Half-Life (t1/2)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2
Reported as:
Mean · hr
Plasma Decay Half-Life (t1/2)
hrCrizotinib 250 mgCrizotinib 250 mg + Rifampin 600 mg
Plasma Decay Half-Life (t1/2)33.07 ± 6.9648.23 ± 5.62
SecondaryApparent Oral Clearance (CL/F)

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose CL/F is influenced by the fraction of the dose absorbed.

Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2
Reported as:
Geometric mean · L/hr
Apparent Oral Clearance (CL/F)
L/hrCrizotinib 250 mgCrizotinib 250 mg + Rifampin 600 mg
Apparent Oral Clearance (CL/F)118.80 ± 37.39648.60 ± 164.95
SecondaryApparent Volume of Distribution (Vz/F)

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2
Reported as:
Geometric mean · L
Apparent Volume of Distribution (Vz/F)
LCrizotinib 250 mgCrizotinib 250 mg + Rifampin 600 mg
Apparent Volume of Distribution (Vz/F)5940.0 ± 3242.945720.0 ± 15766.0
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Crizotinib Metabolite (PF-06260182)

Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast) of crizotinib metabolite (PF-06260182).

Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Crizotinib Metabolite (PF-06260182)
ng*hr/mLCrizotinib 250 mgCrizotinib 250 mg + Rifampin 600 mg
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Crizotinib Metabolite (PF-06260182)369.50 ± 119.5820.28 ± 8.19
Statistical analysis
  • Crizotinib 250 mg vs Crizotinib 250 mg + Rifampin 600 mg · Ratio of adjusted means: 5.49 · 90% CI 4.64 to 6.49
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] for Crizotinib Metabolite (PF-06260182)

AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞) of crizotinib metabolite (PF-06260182). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] for Crizotinib Metabolite (PF-06260182)
ng*hr/mLCrizotinib 250 mgCrizotinib 250 mg + Rifampin 600 mg
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] for Crizotinib Metabolite (PF-06260182)378.60 ± 120.3821.78 ± 8.98
Statistical analysis
  • Crizotinib 250 mg vs Crizotinib 250 mg + Rifampin 600 mg · Ratio of adjusted means: 5.75 · 90% CI 4.86 to 6.81
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) for Crizotinib Metabolite (PF-06260182)
Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax) for Crizotinib Metabolite (PF-06260182)
hrCrizotinib 250 mgCrizotinib 250 mg + Rifampin 600 mg
Time to Reach Maximum Observed Plasma Concentration (Tmax) for Crizotinib Metabolite (PF-06260182)5.0 (4.0 to 8.0)5.0 (2.0 to 6.0)
SecondaryMaximum Observed Plasma Concentration (Cmax) for Crizotinib Metabolite (PF-06260182)
Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Crizotinib Metabolite (PF-06260182)
ng/mLCrizotinib 250 mgCrizotinib 250 mg + Rifampin 600 mg
Maximum Observed Plasma Concentration (Cmax) for Crizotinib Metabolite (PF-06260182)29.88 ± 10.223.29 ± 1.23
Statistical analysis
  • Crizotinib 250 mg vs Crizotinib 250 mg + Rifampin 600 mg · Ratio of adjusted means: 11.01 · 90% CI 9.02 to 13.45
SecondaryMetabolite to Parent Ratio Area Under the Curve From Time Zero to Last Quantifiable Concentration (MRAUClast)

Molar ratio of metabolite to parent area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (MRAUClast).

Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2
Reported as:
Geometric mean · Ratio
Metabolite to Parent Ratio Area Under the Curve From Time Zero to Last Quantifiable Concentration (MRAUClast)
RatioCrizotinib 250 mgCrizotinib 250 mg + Rifampin 600 mg
Metabolite to Parent Ratio Area Under the Curve From Time Zero to Last Quantifiable Concentration (MRAUClast)0.1703 ± 0.02640.0533 ± 0.0112
SecondaryMetabolite to Parent Ratio Area Under the Curve From Time Zero to Extrapolated Infinite Time [MRAUC (0 - ∞)]

Molar ratio of metabolite to parent area under the curve from time zero to extrapolated infinite time \[MRAUC (0-∞)\].

Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose) , 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2
Reported as:
Geometric mean · Ratio
Metabolite to Parent Ratio Area Under the Curve From Time Zero to Extrapolated Infinite Time [MRAUC (0 - ∞)]
RatioCrizotinib 250 mgCrizotinib 250 mg + Rifampin 600 mg
Metabolite to Parent Ratio Area Under the Curve From Time Zero to Extrapolated Infinite Time [MRAUC (0 - ∞)]0.1676 ± 0.02710.0532 ± 0.0113
SecondaryMetabolite to Parent Ratio Maximum Observed Plasma Concentration (MRCmax)

Metabolite to parent molar ratio of maximum observed plasma concentration (MRCmax).

Time frame:
0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 1 and Day 0, 0 (pre-dose), 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 144 hrs post crizotinib dose in period 2
Reported as:
Geometric mean · Ratio
Metabolite to Parent Ratio Maximum Observed Plasma Concentration (MRCmax)
RatioCrizotinib 250 mgCrizotinib 250 mg + Rifampin 600 mg
Metabolite to Parent Ratio Maximum Observed Plasma Concentration (MRCmax)0.2839 ± 0.07110.0996 ± 0.0382

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Crizotinib 250 mg—0/15 (0%)3/15 (20%)
Crizotinib 250 mg + Rifampin 600 mg—0/14 (0%)3/14 (21.4%)
Most frequent other events
Most frequent other events
EventCrizotinib 250 mgCrizotinib 250 mg + Rifampin 600 mg
ConstipationGastrointestinal disorders0/152/14
DiarrhoeaGastrointestinal disorders2/151/14
NauseaGastrointestinal disorders1/150/14
Back painMusculoskeletal and connective tissue disorders1/150/14
EpistaxisRespiratory, thoracic and mediastinal disorders1/150/14
Eye swellingEye disorders0/150/14
HeadacheNervous system disorders0/150/14

Baseline characteristics

Age Continuous
Age Continuous(years)Entire Study Population
Mean38.9 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female1
Male14
08

Study locations

1 site
  • Pfizer Investigational Site
    South Miami, Florida 33143, United States
09

References and documents

Publications

  • Xu H, O'Gorman M, Tan W, Brega N, Bello A. The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects. Eur J Clin Pharmacol. 2015 Dec;71(12):1441-9. doi: 10.1007/s00228-015-1945-5. Epub 2015 Sep 18. PubMed 26381275 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2010
First posted
Jun 22, 2010
Start
Jul 2010
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results first posted
Oct 19, 2011
Last update
Oct 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01147055
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 22, 2010
Start date
Jul 2010
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Oct 19, 2011
Last update
Oct 24, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crizotinib

Start the discussion